[go: up one dir, main page]

SG10201805815YA - Rna-guided gene drives - Google Patents

Rna-guided gene drives

Info

Publication number
SG10201805815YA
SG10201805815YA SG10201805815YA SG10201805815YA SG10201805815YA SG 10201805815Y A SG10201805815Y A SG 10201805815YA SG 10201805815Y A SG10201805815Y A SG 10201805815YA SG 10201805815Y A SG10201805815Y A SG 10201805815YA SG 10201805815Y A SG10201805815Y A SG 10201805815YA
Authority
SG
Singapore
Prior art keywords
rna
guided
dna
gene drives
present disclosure
Prior art date
Application number
SG10201805815YA
Inventor
Kevin Esvelt
Andrea L Smidler
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of SG10201805815YA publication Critical patent/SG10201805815YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/905—Stable introduction of foreign DNA into chromosome using homologous recombination in yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

RNA-GUIDED GENE DRIVES RNA guided Cas9 gene drives and method for their use are disclosed. Embodiments of the present disclosure are based on the use of RNA guided DNA binding proteins to co- localize with guide RNA at a target DNA site and act as gene drives. DNA binding proteins included within the scope of the present disclosure include those which may be guided by RNA, referred to herein as guide RNA. DNA binding include naturally occurring DNA 10 binding proteins having nuclease activity, such as Cas9 proteins. According to one aspect, the enzyme of the present disclosure, such as Cas9 unwinds the DNA duplex and searches for sequences matching the crRNA to cleave. FIG. 1 15 85
SG10201805815YA 2014-01-08 2015-01-08 Rna-guided gene drives SG10201805815YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461924735P 2014-01-08 2014-01-08
US201462024642P 2014-07-15 2014-07-15

Publications (1)

Publication Number Publication Date
SG10201805815YA true SG10201805815YA (en) 2018-08-30

Family

ID=53524319

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201805815YA SG10201805815YA (en) 2014-01-08 2015-01-08 Rna-guided gene drives
SG11201605550QA SG11201605550QA (en) 2014-01-08 2015-01-08 Rna-guided gene drives

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201605550QA SG11201605550QA (en) 2014-01-08 2015-01-08 Rna-guided gene drives

Country Status (9)

Country Link
US (1) US10526618B2 (en)
EP (1) EP3092310B1 (en)
JP (2) JP6747974B2 (en)
CN (1) CN106133141B (en)
AU (2) AU2015204784B2 (en)
CA (1) CA2936312A1 (en)
SG (2) SG10201805815YA (en)
WO (1) WO2015105928A1 (en)
ZA (1) ZA201604874B (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (en) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ Evaluation and improvement of nuclease cleavage specificity
EP4481048A3 (en) 2012-12-17 2025-02-26 President and Fellows of Harvard College Rna-guided human genome engineering
CN104995302B (en) 2013-01-16 2021-08-31 爱默蕾大学 CAS9-nucleic acid complexes and related uses
RS62263B1 (en) 2013-04-16 2021-09-30 Regeneron Pharma Targeted modification of rat genome
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
PT3066201T (en) 2013-11-07 2018-06-04 Massachusetts Inst Technology METHODS AND COMPOSITIONS RELATED TO CRISPR WITH REGULATORY RANGES
RU2725520C2 (en) 2013-12-11 2020-07-02 Регенерон Фармасьютикалс, Инк. Methods and compositions for genome targeted modification
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
EP3161128B1 (en) 2014-06-26 2018-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2016018960A1 (en) 2014-07-30 2016-02-04 President And Fellows Of Harvard College Systems and methods for determining nucleic acids
WO2016073559A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing
IL301900A (en) 2014-11-21 2023-06-01 Regeneron Pharma Methods and preparations for targeted genetic modification using paired guide RNA
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
WO2017058839A1 (en) * 2015-10-02 2017-04-06 President And Fellows Of Harvard College Dependent component genome editing gene drives
WO2017058888A1 (en) * 2015-10-02 2017-04-06 Agenovir Corporation Transgenic nuclease systems and methods
EP3365356B1 (en) 2015-10-23 2023-06-28 President and Fellows of Harvard College Nucleobase editors and uses thereof
WO2017196768A1 (en) * 2016-05-09 2017-11-16 President And Fellows Of Harvard College Self-targeting guide rnas in crispr system
WO2017196858A1 (en) * 2016-05-09 2017-11-16 Massachusetts Institute Of Technology Methods to design and use gene drives
JP7231935B2 (en) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Adenosine nucleobase editors and their uses
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US20210000091A1 (en) * 2016-08-17 2021-01-07 The Regents Of The University Of California Split Trans-Complementing Gene-Drive System for Suppressing Aedes Aegypti Mosquitos
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US20190241879A1 (en) * 2016-09-09 2019-08-08 Massachusetts Institute Of Technology Methods and compounds for gene insertion into repeated chromosome regions for multi-locus assortment and daisyfield drives
JP2019526271A (en) 2016-09-13 2019-09-19 ツールゲン インコーポレイテッドＴｏｏｌｇｅｎ Ｉｎｃｏｒｐｏｒａｔｅｄ Method for confirming base editing in DNA using cytosine deaminase
EP3526320A1 (en) 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
TW201839136A (en) 2017-02-06 2018-11-01 瑞士商諾華公司 Composition and method for treating hemochromatosis
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (en) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cytosine to Guanine Base Editing Agent
KR20240116572A (en) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018179578A1 (en) * 2017-03-30 2018-10-04 国立大学法人京都大学 Method for inducing exon skipping by genome editing
WO2018127611A1 (en) * 2017-04-06 2018-07-12 Dsm Ip Assets B.V. Self-guiding integration construct (sgic)
CN116555353A (en) 2017-04-20 2023-08-08 E开创生物技术股份有限公司 Method for producing genetically modified animals
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019067011A1 (en) * 2017-09-29 2019-04-04 Kansas State University Research Foundation Programmed modulation of crispr/cas9 activity
CN111757937A (en) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 Uses of adenosine base editors
US20200367479A1 (en) * 2017-11-21 2020-11-26 The Regents Of The University Of California Endonuclease sexing and sterilization in insects
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN108285892A (en) * 2018-02-01 2018-07-17 上海市东方医院 A kind of stable human endogenous Ito of generation, the cell model and construction method of s electric currents and application
CN112088215A (en) * 2018-05-09 2020-12-15 帝斯曼知识产权资产管理有限公司 CRISPR Transient Expression Constructs (CTEC)
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12344837B2 (en) 2018-05-29 2025-07-01 Buck Institute For Research On Aging Gene-drive in DNA viruses
GB201810253D0 (en) * 2018-06-22 2018-08-08 Imperial Innovations Ltd Gene drive
MA52107B1 (en) 2018-07-18 2022-11-30 Plantarcbio Ltd Compositions and methods for mitigating rhynchophorus ferrugineus pest infestation
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
US12391685B2 (en) 2018-08-20 2025-08-19 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease target binding and uses thereof
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
EP3894583A4 (en) 2018-12-13 2022-11-09 President and Fellows of Harvard College AMPLIFICATION SYSTEMS AND METHODS FOR MERFISH AND OTHER APPLICATIONS
US12264323B2 (en) 2018-12-17 2025-04-01 The Broad Institute, Inc. CRISPR CPF1 direct repeat variants
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (en) 2019-03-19 2022-03-11 Broad Inst Inc METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES.
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
AU2020258458A1 (en) * 2019-04-19 2021-11-18 President And Fellows Of Harvard College Imaging-based pooled CRISPR screening
GB201906203D0 (en) * 2019-05-02 2019-06-19 Pirbright Inst Method
AU2020347276A1 (en) 2019-09-12 2022-03-17 Massachusetts Institute Of Technology Engineered adeno-associated virus capsids
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021146641A1 (en) 2020-01-17 2021-07-22 The Broad Institute, Inc. Small type ii-d cas proteins and methods of use thereof
MX2022014008A (en) 2020-05-08 2023-02-09 Broad Inst Inc Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence.
US20240409959A1 (en) * 2021-10-12 2024-12-12 The Regents Of The University Of California Gene drive system and method of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0126251D0 (en) * 2001-11-01 2002-01-02 Imp College Innovations Ltd Methods
US20120315670A1 (en) * 2009-11-02 2012-12-13 Gen9, Inc. Compositions and Methods for the Regulation of Multiple Genes of Interest in a Cell
SG11201405103SA (en) * 2012-02-24 2014-09-26 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
GB2500113A (en) * 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
WO2013141680A1 (en) * 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
EP2847338B1 (en) * 2012-05-07 2018-09-19 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
MY189533A (en) * 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2013188638A2 (en) * 2012-06-15 2013-12-19 The Regents Of The University Of California Endoribonucleases and methods of use thereof
EP2861737B1 (en) * 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
RU2725520C2 (en) * 2013-12-11 2020-07-02 Регенерон Фармасьютикалс, Инк. Methods and compositions for genome targeted modification

Also Published As

Publication number Publication date
CA2936312A1 (en) 2015-07-16
WO2015105928A9 (en) 2015-09-24
ZA201604874B (en) 2022-08-31
EP3092310A1 (en) 2016-11-16
JP2017511685A (en) 2017-04-27
EP3092310B1 (en) 2019-12-25
JP2021003112A (en) 2021-01-14
AU2021202590A1 (en) 2021-05-27
AU2015204784B2 (en) 2021-01-28
CN106133141A (en) 2016-11-16
EP3092310A4 (en) 2017-11-22
AU2015204784A1 (en) 2016-07-21
JP6747974B2 (en) 2020-08-26
WO2015105928A1 (en) 2015-07-16
BR112016015958A2 (en) 2017-09-19
US20160333376A1 (en) 2016-11-17
JP7187508B2 (en) 2022-12-12
US10526618B2 (en) 2020-01-07
SG11201605550QA (en) 2016-08-30
CN106133141B (en) 2021-08-20

Similar Documents

Publication Publication Date Title
SG10201805815YA (en) Rna-guided gene drives
HK1258900A1 (en) Delivery methods and compositions
BR112015023489A2 (en) use of truncads rna-guide (tru-grnas) to increase specificity of guided rna genome editing
PT3765616T (en) Novel crispr dna and rna targeting enzymes and systems
MX377162B (en) NEW ENZYMES AND CRISPR SYSTEMS
WO2018129368A3 (en) Methods of assessing nuclease cleavage
EP4400597A3 (en) Novel rna-guided nucleases and uses thereof
EP3617309A3 (en) Crispr-based genome modification and regulation
WO2016183402A3 (en) Methods of making and using guide rna for use with cas9 systems
MX2018001617A (en) Engineered crispr-cas9 compositions and methods of use.
MX373898B (en) Compositions and methods for the expression of crispr guide rnas using the h1 promoter
PH12019500626A1 (en) Aav treatment of huntington's disease
EP3845640A3 (en) Modified tranposases for improved insertion sequence bias and increased dna input tolerence
NZ727481A (en) Methods and compositions for modifying a targeted locus
MX2019003678A (en) Rna-guided nucleic acid modifying enzymes and methods of use thereof.
EP4269577A3 (en) Nucleobase editors and uses thereof
MX388784B (en) METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION THROUGH SINGLE-STEP MULTIPLE TARGETING.
WO2016205688A3 (en) Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
WO2015112896A3 (en) Methods and compositions for sequences guiding cas9 targeting
GEP20217251B (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
UA118090C2 (en) Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
SG10201804715WA (en) Crispr hybrid dna/rna polynucleotides and methods of use
SG10201809312QA (en) Nucleic acid synthesis techniques
HK1246180A1 (en) Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
MX388127B (en) METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME.